Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
4DMedical Ltd ( (AU:4DX) ) has issued an announcement.
4DMedical Limited, a global medtech company specialising in AI-enhanced respiratory imaging, develops and commercialises software solutions such as XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, all delivered through a SaaS model for seamless integration into hospital systems. Its patented XV Technology converts standard imaging into rich functional data, enabling earlier and more accurate detection and management of lung disease and strengthening its position in advanced cardiothoracic imaging.
The company disclosed changes in director interests, with Dr. Geraldine McGinty acquiring 213,464 ordinary shares and Dr. Robert Figlin acquiring 302,750 ordinary shares through the conversion of Restricted Stock Units. These awards increase insider equity holdings without cash consideration, aligning board members more closely with shareholder outcomes and signalling continued confidence in 4DMedical’s long-term growth trajectory in respiratory imaging and AI-driven diagnostics.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company focused on revolutionising respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard lung scans into detailed functional insights, supporting earlier and more precise detection, diagnosis and monitoring of lung disease. The company offers a growing software portfolio, including FDA-cleared XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, delivered via a SaaS model that integrates into existing hospital infrastructure. With added AI capabilities from its 2023 acquisition of Imbio, 4DMedical aims to redefine how respiratory disease is understood and treated worldwide.
Average Trading Volume: 6,896,428
Technical Sentiment Signal: Buy
Current Market Cap: A$2.41B
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.